IP Library Granted Patent US 7,615,543
Granted Patent B2
US 7,615,543 · App. 10/514,127 · Granted Nov 10, 2009

Treatment and prevention of tissue damage

Assignee: Pentraxin Therapeutics Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,615,543
App. No.
10/514,127
Granted
Nov 10, 2009
Kind
B2
Abstract

An agent for use in medicine, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of C-reactive protein (CRP) molecules in the presence thereof, wherein (i) at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the CRP molecules; or (ii) at least one of the ligands is capable of being bound by a ligand binding site present on a CRP molecule, and at least one other of the ligands is capable of being bound by a ligand binding site present on a serum amyloid P component (SAP) molecule.

Claims (13)

1. A method for the treatment of tissue damage in a subject having an inflammatory and/or tissue damaging condition caused by C-reactive protein (CRP) comprising atherosclerosis, an inflammatory disease, ischemic or other necrosis, traumatic tissue damage, malignant neoplasia, a bacterial infection, a viral infection, a parasitic infection, or an allergic complication of infection selected from the group consisting of rheumatic fever, glomerulonephritis, and erythema nodosum leprosum, and in need of such treatment, which comprises administering to the subject an effective amount of an agent having the general structure of

Ligand-liniker-Ligand

wherein each Ligand has the general formula:

in which R is an amine linked to the —O— by an alkylene group;

wherein the linker has a linear chain structure of —CH 2 (CH 2 )CH 2 — with y having a value from 3 to 18 and the linker enables formation of a complex with CRP in the presence thereof,

wherein

the Ligands are the same or different, and

bind to CRP by ligand binding sites present on CRP.

2. The method according to claim 1 wherein the Ligands are the same.

3. The method according to claim 1 , wherein the condition is an inflammatory disease selected from rheumatoid arthritis, juvenile chronic (rheumatoid) arthritis, ankylosing spondylitis, psoriatic arthritis, systemic vasculitis, polymyalgia rheumatica, Reiter's disease, Crohn's disease and familial Mediterranean fever.

4. The method according to claim 1 , wherein the condition is tissue necrosis due to anyone of myocardial infarcation, ischaemic stroke, tumour embolization, and acute pancreatitis.

5. The method according to claim 1 , wherein the condition is trauma selected from elective surgery, burns, chemical injury, fractures and compression injury.

6. The method according to claim 1 , wherein the condition is malignant neoplasia selected from lymphoma, Hodgkin's disease, carcinoma and sarcoma.

Assignments (2)
CHANGE OF ASSIGNEE ADDRESS Recorded Jan 10, 2012
From: PENTRAXIN THERAPEUTICS LIMITED
To: PENTRAXIN THERAPEUTICS LIMITED
Reel/Frame 027506/0748 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2007
From: PEPYS, MARK B.
To: PENTRAXIN THERAPEUTICS LIMITED
Reel/Frame 020046/0301 →
Priority Claims (1)
GB 0211136.7 · May 15, 2002 · national
Continuity (1)
Related Publication 20060019930A1 · Jan 26, 2006